Sensus Healthcare Stock Intrinsic Value – SENSUS HEALTHCARE Reports Q2 2023 Results, June 30, 2023
August 24, 2023
🌥️Earnings Overview
For the second quarter of 2023, SENSUS HEALTHCARE ($NASDAQ:SRTS) reported a dramatic 62.5% decrease in total revenue, amounting to USD 4.5 million. This is a sharp contrast to the same quarter of the previous year, when they earned USD 3.52 million in net income.
Stock Price
SENSUS HEALTHCARE released their financial report for Q2 2023 on Thursday, June 30th. The company saw a 5.6% drop in stock price from the prior closing price of $2.9, opening at $2.8 and closing at $2.7. Despite the drop in stock price, the company saw increases in revenue and net income, as well as decreased expenses.
SENSUS HEALTHCARE’s earnings report revealed that the company has had successful efforts in controlling costs while increasing revenue and net income. The company continues to grow while maintaining cost-effective operations, putting them in a strong position to continue to expand and succeed over the coming years. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Sensus Healthcare. More…
| Total Revenues | Net Income | Net Margin |
| 30.06 | 2.38 | 7.9% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Sensus Healthcare. More…
| Operations | Investing | Financing |
| -10.49 | 14.84 | -2.43 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Sensus Healthcare. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 52.02 | 6.01 | 2.81 |
Key Ratios Snapshot
Some of the financial key ratios for Sensus Healthcare are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 20.4% | – | 8.7% |
| FCF Margin | ROE | ROA |
| -35.9% | 3.5% | 3.2% |
Analysis – Sensus Healthcare Stock Intrinsic Value
At GoodWhale, we recently conducted an analysis of SENSUS HEALTHCARE’s wellbeing. After running our proprietary Valuation Line, we have determined that the fair value of SENSUS HEALTHCARE share is around $6.8. Currently, SENSUS HEALTHCARE stock is being traded at $2.7, which is significantly undervalued by 60.4%. We believe that SENSUS HEALTHCARE stock is an attractive option for investors who are looking for good returns in the market. More…
Peers
The company’s products include radiation therapy systems and products for treating cancer with lasers. The company’s products are used by hospitals, clinics, and physicians. The company has a wide range of products and services, and it offers a variety of options for cancer treatments. The company’s products are competitively priced, and the company offers a variety of financing options.
– Apollo Endosurgery Inc ($NASDAQ:APEN)
Apollo Endosurgery Inc is a medical device company that focuses on developing less invasive surgical treatments. As of 2022, the company has a market capitalization of 271.04 million and a return on equity of -42.15%. The company’s products are used in a variety of procedures, including gastrointestinal, bariatric, and thoracic surgery. Apollo Endosurgery Inc has a strong research and development team that is constantly working to improve existing products and develop new ones. The company’s products are sold in over 60 countries around the world.
– InfuSystems Holdings Inc ($NYSEAM:INFU)
InfuSystems Holdings Inc is a company that provides infusion pumps and related services to the healthcare industry. The company has a market cap of 177.64M as of 2022 and a Return on Equity of 2.81%. The company’s products are used in the treatment of cancer, pain management, and other chronic conditions. The company’s products are sold through a network of distributors and dealers in the United States and Canada.
– Bone Biologics Corp ($NASDAQ:BBLG)
Bone Biologics Corp is a biotechnology company that focuses on the development of novel therapeutics for the treatment of bone diseases. The company’s market cap is 3.99M as of 2022. Its ROE is -16.65%. The company’s products are designed to improve the quality of life for patients with bone diseases.
Summary
SENSUS HEALTHCARE reported disappointing second quarter results for the fiscal year 2023, with total revenue dropping a massive 62.5% to USD 4.5 million, and a net loss of USD -0.38 million. The stock price for the company followed suit and dropped the same day. Investors should be cautious and consider the risks before investing in SENSUS HEALTHCARE. Those who have already invested should take a closer look at the company’s financial situation and consider strategies to mitigate their losses, including diversifying their portfolios.
Related Posts
Recent Posts
